AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35791845 — intervention group
Group type: COMPARATOR
Intervention: Ultra‐pulsed CO2 fractional laser
Number of subjects: 20
Study 33392782 — intervention group
Group type: EXPERIMENTAL
Intervention: 940 nm laser diode irradiation (Epic 10, Biolase, USA) at 100 mW for 5 seconds
Number of subjects: 30
Study 33392782 — intervention group
Group type: COMPARATOR
Intervention: Control group (aiming beam only)
Number of subjects: 30
Study 32050663 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals living close to forested areas
Number of subjects: 1200
Study 32050663 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals in areas with high population density (>400 people per km2)
Number of subjects: 1200
Study 32050663 — intervention group
Group type: EXPERIMENTAL
Intervention: General population density
Number of subjects: 1200
Study 32050663 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional gold mining activities
Number of subjects: 1200
Study 32541215 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral feeding (DOF)
Number of subjects: 196
Study 32541215 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (nil‐by‐mouth for 5 days postoperative and tube feeding)
Number of subjects: 196
Study 32541215 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care)
Number of subjects: 196
Study 32667428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibullying intervention consisting of two meetings focused on educative aspects of bullying, with 613 (58.7%) adolescents participating.
Number of subjects: 1043
Study 32667428 — intervention group
Group type: COMPARATOR
Intervention: Control group consisting of 430 (41.3%) participants who did not receive the intervention.
Number of subjects: 1043
Study 35405479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual cessation strategy (reduce baseline number of cigarettes per day by 25% over a 4 week period)
Number of subjects: 66
Study 35405479 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation strategy (assigned a quit date the day they were provided their VNP)
Number of subjects: 66
Study 35007321 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 168
Study 35007321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-α (PEG)
Number of subjects: 168
Study 35007321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 168
Study 33711123 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavyweight mesh
Number of subjects: 412
Study 33711123 — intervention group
Group type: COMPARATOR
Intervention: Lightweight mesh
Number of subjects: 412
Study 35355382 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX-implant
Number of subjects: 52
Study 35355382 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 52
Study 34003273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative use duration of more than 90 days
Number of subjects: 1511
Study 34003273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily dose higher than 90 MME
Number of subjects: 1511
Study 34003273 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related emergency department visits, hospital readmissions, or all-cause death
Number of subjects: 1511
Study 32380917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive training
Number of subjects: 92
Study 32380917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training alone
Number of subjects: 92
Study 32380917 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 92
Study 32380917 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 92
Study 35334136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 760
Study 35334136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 33850184 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ1a (subcutaneous injections of 12,000 IU on days 1, 3, 6)
Number of subjects: 60
Study 33850184 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ1b (subcutaneous injections of 8,000,000 IU on days 1, 3, 6)
Number of subjects: 60
Study 33850184 — intervention group
Group type: COMPARATOR
Intervention: Control group (Lopinavir/Ritonavir and Hydroxychloroquine)
Number of subjects: 60
Study 37487868 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG13.5-IUD
Number of subjects: 106
Study 37487868 — intervention group
Group type: COMPARATOR
Intervention: Cu380-IUD
Number of subjects: 106
Study 34340527 — intervention group
Group type: EXPERIMENTAL
Intervention: THX‐110 (∆9‐THC 10 mg daily and PEA 800 mg daily)
Number of subjects: 16
Study 33103934 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota analysis and profiling
Number of subjects: 0
Study 33103934 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature review of factors affecting CD onset
Number of subjects: 0
Study 33103934 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion on disease modification and prevention
Number of subjects: 0
Study 32320061 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 99
Study 32320061 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 99
Study 32827412 — intervention group
Group type: EXPERIMENTAL
Intervention: NR-INF-02 at 1000 mg for 84 days
Number of subjects: 48
Study 32827412 — intervention group
Group type: EXPERIMENTAL
Intervention: NR-INF-02 at 2000 mg for 84 days
Number of subjects: 48
Study 32827412 — intervention group
Group type: EXPERIMENTAL
Intervention: NR-INF-02 (both doses)
Number of subjects: 48
Study 35134185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine as post-exposure prophylaxis
Number of subjects: 689
Study 35134185 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to two suspected index cases
Number of subjects: 689
Study 35134185 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased contact time for healthcare workers
Number of subjects: 689
Study 35134185 — intervention group
Group type: COMPARATOR
Intervention: County-level incidence
Number of subjects: 689
Study 34015499 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich seaweed extract (2000 mg/d)
Number of subjects: 34
Study 34015499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32886710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hero program (experimental group)
Number of subjects: 909
Study 32886710 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 909
Study 36402056 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-based educative psycho-behavioral program (n=86)
Number of subjects: 171
Study 36402056 — intervention group
Group type: COMPARATOR
Intervention: Generic health education program (n=85)
Number of subjects: 171
Study 32266392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine device (IUD) provided during surgical TOP or 1-4 weeks following medical TOP.
Number of subjects: 748
Study 32266392 — intervention group
Group type: COMPARATOR
Intervention: Control group advised to contact primary health care for follow-up and IUD insertion.
Number of subjects: 748
Study 32266392 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD intervention during years 0-3.
Number of subjects: 748
Study 32266392 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD intervention during years 4-5.
Number of subjects: 748
Study 32266392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall requested TOPs including TOPs and early pregnancy failures in intervention group.
Number of subjects: 748
Study 32266392 — intervention group
Group type: COMPARATOR
Intervention: Overall requested TOPs including TOPs and early pregnancy failures in control group.
Number of subjects: 748
Study 32266392 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent TOPs overall in intervention group.
Number of subjects: 748
Study 32266392 — intervention group
Group type: COMPARATOR
Intervention: Subsequent TOPs overall in control group.
Number of subjects: 748
Study 36215000 — intervention group
Group type: EXPERIMENTAL
Intervention: WL+EX
Number of subjects: 112
Study 36215000 — intervention group
Group type: EXPERIMENTAL
Intervention: WL+SL
Number of subjects: 112
Study 36215000 — intervention group
Group type: EXPERIMENTAL
Intervention: WL+EX+SL
Number of subjects: 112
Study 34185574 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted re-instruction on hearing aid use and care skills
Number of subjects: 26
Study 34185574 — intervention group
Group type: COMPARATOR
Intervention: Standard HA orientation (Control)
Number of subjects: 26
Study 32664361 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) during exercise
Number of subjects: 34
Study 32664361 — intervention group
Group type: COMPARATOR
Intervention: Control group (aerobic and strength training without WB-EMS)
Number of subjects: 34
Study 35363205 — intervention group
Group type: EXPERIMENTAL
Intervention: Online rational emotive behavior therapy (online REBT)
Number of subjects: 35
Study 35363205 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 35
Study 32049065 — intervention group
Group type: EXPERIMENTAL
Intervention: Push notifications and access to app functionalities
Number of subjects: 117
Study 32049065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to app functionalities)
Number of subjects: 117
Study 35177279 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod (IMQ) therapy for 16 weeks
Number of subjects: 93
Study 35177279 — intervention group
Group type: COMPARATOR
Intervention: Large loop excision of the transformation zone (LLETZ)
Number of subjects: 93
Study 34453917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflations
Number of subjects: 70
Study 34453917 — intervention group
Group type: COMPARATOR
Intervention: IPPV
Number of subjects: 70
Study 34453917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 35091786 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-monitoring of blood pressure (BP) for 2 months
Number of subjects: 161
Study 35091786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple self-monitoring (BP, body fat, sleeping time, daily step count) for 2 months
Number of subjects: 161
Study 35091786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-monitoring) for 2 months
Number of subjects: 161
Study 35173011 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door policy (ODP)
Number of subjects: 0
Study 35173011 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 32421486 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural matrix biopolymer membrane (NMBM)
Number of subjects: 25
Study 32421486 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 25
Study 36197415 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) program with a progressive resistive load of 40‐70% of the maximum inspiratory pressure (PImax) for 30 breaths once a day for 12 weeks
Number of subjects: 65
Study 36197415 — intervention group
Group type: COMPARATOR
Intervention: Control group with a similar protocol at a minimum load of 10 cmH2O
Number of subjects: 65
Study 33792038 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D simulation
Number of subjects: 20
Study 33792038 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simulation
Number of subjects: 20
Study 33792038 — intervention group
Group type: COMPARATOR
Intervention: 2D simulation
Number of subjects: 20
Study 32382078 — intervention group
Group type: EXPERIMENTAL
Intervention: ExoDx Prostate(IntelliScore) (EPI) test
Number of subjects: 1094
Study 32382078 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard of care)
Number of subjects: 1094
Study 35930874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention
Number of subjects: 605
Study 35930874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem intervention
Number of subjects: 605
Study 35930874 — intervention group
Group type: COMPARATOR
Intervention: Benign recollection control
Number of subjects: 605
Study 32028078 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Gait Efficacy Scale (mGES)
Number of subjects: 424
Study 32028078 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened mGES (removing certain items)
Number of subjects: 424
Study 32028078 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-item version of mGES
Number of subjects: 424
Study 34297780 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe depression
Number of subjects: 1007
Study 34297780 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe anxiety
Number of subjects: 1007
Study 32458096 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid treatment
Number of subjects: 155
Study 34301203 — intervention group
Group type: EXPERIMENTAL
Intervention: P02 hearing aid
Number of subjects: 73
Study 34301203 — intervention group
Group type: COMPARATOR
Intervention: Clip‐II™
Number of subjects: 73
Study 34301203 — intervention group
Group type: COMPARATOR
Intervention: Concerto Basic®
Number of subjects: 73
Study 32209082 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop intervention
Number of subjects: 25
Study 32209082 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 25
Study 34469077 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed microvascular tissue (PMVT) allograft
Number of subjects: 100
Study 34469077 — intervention group
Group type: COMPARATOR
Intervention: Collagen alginate dressing
Number of subjects: 100
Study 33100181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment (low dose regimen, 40 mg)
Number of subjects: 46
Study 33100181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment
Number of subjects: 46
Study 35997638 — intervention group
Group type: EXPERIMENTAL
Intervention: Indira Gandhi Matritva Sahyog Yojana (IGMSY)
Number of subjects: 52
Study 35997638 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treatment districts)
Number of subjects: 52
Study 32306747 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 88
Study 32306747 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (general practice medical care)
Number of subjects: 88
Study 35170379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cake and juice consumption 30 minutes before NST
Number of subjects: 360
Study 35170379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cake and juice consumption + motivational video (15-20 minutes) during NST
Number of subjects: 360
Study 35170379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 360
Study 33595176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk drinkers (n=275)
Number of subjects: 1760
Study 33595176 — intervention group
Group type: COMPARATOR
Intervention: Moderate drinkers (n=1222)
Number of subjects: 1760
Study 33595176 — intervention group
Group type: COMPARATOR
Intervention: Former drinkers (n=263)
Number of subjects: 1760
Study 33595176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk drinkers (n=275) with metabolic syndrome (MS)
Number of subjects: 1760
Study 33595176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk drinkers (n=275) with high alcohol consumption
Number of subjects: 1760
Study 34857420 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of bivalent HPV vaccine
Number of subjects: 20330
Study 34857420 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of bivalent HPV vaccine
Number of subjects: 20330
Study 34857420 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of nonavalent HPV vaccine
Number of subjects: 20330
Study 34857420 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of nonavalent HPV vaccine
Number of subjects: 20330
Study 34857420 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 20330
Study 33825687 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT), 8-week intervention, therapist-guided
Number of subjects: 63
Study 33825687 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 63
Study 33825687 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 63
Study 36201851 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group weight management program, ShipShape
Number of subjects: 178
Study 36201851 — intervention group
Group type: COMPARATOR
Intervention: ShipShape enhanced with acceptance and commitment therapy
Number of subjects: 178
Study 32633067 — intervention group
Group type: EXPERIMENTAL
Intervention: FVIII concentration measured with liquid chromatography‐tandem mass spectrometry (LC‐MS/MS)
Number of subjects: 87
Study 32633067 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti‐FVIII antibodies
Number of subjects: 87
Study 32633067 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of exogenous FVIII products
Number of subjects: 87
Study 34380854 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational-supportive program in 3 weekly sessions
Number of subjects: 140
Study 34380854 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 140
Study 32029537 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced risk claim
Number of subjects: 450
Study 32029537 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced exposure claim
Number of subjects: 450
Study 32029537 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither claim)
Number of subjects: 450
Study 35255096 — intervention group
Group type: COMPARATOR
Intervention: Thermotherapy (TT)
Number of subjects: 130
Study 35255096 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy (TT) plus a short course of miltefosine (MLT)
Number of subjects: 130
Study 34006388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) oil soft gelatin capsules 450 mg twice daily
Number of subjects: 117
Study 34006388 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (LM)
Number of subjects: 117
Study 34006388 — intervention group
Group type: COMPARATOR
Intervention: Metformin (Met) 500 mg tablets twice daily
Number of subjects: 117
Study 32917187 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program on Nursing Informatics (NI) competency delivered in a three-day workshop.
Number of subjects: 60
Study 32917187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 60
Study 35093682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncotype DX test
Number of subjects: 10000
Study 35093682 — intervention group
Group type: COMPARATOR
Intervention: EndoPredict test
Number of subjects: 10000
Study 35093682 — intervention group
Group type: COMPARATOR
Intervention: MammaPrint test
Number of subjects: 10000
Study 35093682 — intervention group
Group type: COMPARATOR
Intervention: Prosigna test
Number of subjects: 10000
Study 33573741 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for ischemic mitral valve regurgitation (IMR)
Number of subjects: 492
Study 32349193 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 233
Study 32349193 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 0.5 mg
Number of subjects: 233
Study 32349193 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (subgroup with preserved LVEF)
Number of subjects: 233
Study 35568490 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with water and wood ash
Number of subjects: 440
Study 35568490 — intervention group
Group type: COMPARATOR
Intervention: Handwashing with water alone
Number of subjects: 440
Study 36227509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring (isCGM) system
Number of subjects: 122
Study 32043342 — intervention group
Group type: COMPARATOR
Intervention: HIIT
Number of subjects: 30
Study 32043342 — intervention group
Group type: COMPARATOR
Intervention: CA
Number of subjects: 30
Study 32043342 — intervention group
Group type: EXPERIMENTAL
Intervention: CA+NMES
Number of subjects: 30
Study 32043342 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT+NMES
Number of subjects: 30
Study 33740348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine group (0.375% ropivacaine)
Number of subjects: 0
Study 33740348 — intervention group
Group type: COMPARATOR
Intervention: Saline group (mock ESPB with saline)
Number of subjects: 0
Study 32497783 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support arm
Number of subjects: 296
Study 32497783 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care arm
Number of subjects: 296
Study 35281316 — intervention group
Group type: EXPERIMENTAL
Intervention: YYD601 30 mg
Number of subjects: 32
Study 35281316 — intervention group
Group type: EXPERIMENTAL
Intervention: YYD601 40 mg
Number of subjects: 32
Study 35281316 — intervention group
Group type: EXPERIMENTAL
Intervention: YYD601 60 mg
Number of subjects: 32
Study 35281316 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 32
Study 33462323 — intervention group
Group type: EXPERIMENTAL
Intervention: Late implant placement following alveolar ridge preservation (LP/ARP)
Number of subjects: 16
Study 33462323 — intervention group
Group type: EXPERIMENTAL
Intervention: Early implantation (EP)
Number of subjects: 16
Study 32998920 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intravenous dexamethasone
Number of subjects: 80
Study 32998920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34263442 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection (DH)
Number of subjects: 78
Study 32345649 — intervention group
Group type: EXPERIMENTAL
Intervention: cRGD-ZW800-1 at 0.05 mg/kg
Number of subjects: 12
Study 32345649 — intervention group
Group type: EXPERIMENTAL
Intervention: cRGD-ZW800-1 at 0.005 mg/kg
Number of subjects: 12
Study 32345649 — intervention group
Group type: EXPERIMENTAL
Intervention: cRGD-ZW800-1 at 0.015 mg/kg
Number of subjects: 12
Study 32345649 — intervention group
Group type: EXPERIMENTAL
Intervention: cRGD-ZW800-1
Number of subjects: 12